[go: up one dir, main page]

WO2010115830A3 - Agent pharmaceutique - Google Patents

Agent pharmaceutique Download PDF

Info

Publication number
WO2010115830A3
WO2010115830A3 PCT/EP2010/054378 EP2010054378W WO2010115830A3 WO 2010115830 A3 WO2010115830 A3 WO 2010115830A3 EP 2010054378 W EP2010054378 W EP 2010054378W WO 2010115830 A3 WO2010115830 A3 WO 2010115830A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical agent
pharmaceutically active
active moiety
metabolised
transforming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/054378
Other languages
English (en)
Other versions
WO2010115830A2 (fr
Inventor
Gregory Alan Stoloff
Wilson Romero Caparros-Wanderley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptcell Ltd
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of WO2010115830A2 publication Critical patent/WO2010115830A2/fr
Publication of WO2010115830A3 publication Critical patent/WO2010115830A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent pharmaceutique comprenant un fragment pharmaceutiquement actif capable de transformer un sucre, de préférence un glucose, en un composé qui n'est pas métabolisé. Ledit fragment pharmaceutiquement actif n'a pas d'effet négatif sur la composition sanguine ni sur les caractéristiques sanguines.
PCT/EP2010/054378 2009-03-31 2010-03-31 Agent pharmaceutique Ceased WO2010115830A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0905555.9 2009-03-31
GBGB0905555.9A GB0905555D0 (en) 2009-03-31 2009-03-31 Pharmaceutical agent

Publications (2)

Publication Number Publication Date
WO2010115830A2 WO2010115830A2 (fr) 2010-10-14
WO2010115830A3 true WO2010115830A3 (fr) 2010-12-23

Family

ID=40672044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/054378 Ceased WO2010115830A2 (fr) 2009-03-31 2010-03-31 Agent pharmaceutique

Country Status (2)

Country Link
GB (1) GB0905555D0 (fr)
WO (1) WO2010115830A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345964A (zh) * 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——己糖激酶10.01和编码这种多肽的多核苷酸
WO2003020963A2 (fr) * 2001-09-05 2003-03-13 Pride Proteomics A/S Proteines impliquees dans le diabete de type 2
WO2004091494A2 (fr) * 2003-04-11 2004-10-28 Pr Pharmaceuticals Inc. Procede de preparation de conjugues de proteines specifiques de site
WO2007128901A1 (fr) * 2006-04-27 2007-11-15 Compagnie Laitiere Europeenne Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1345964A (zh) * 2000-09-29 2002-04-24 上海博德基因开发有限公司 一种新的多肽——己糖激酶10.01和编码这种多肽的多核苷酸
WO2003020963A2 (fr) * 2001-09-05 2003-03-13 Pride Proteomics A/S Proteines impliquees dans le diabete de type 2
WO2004091494A2 (fr) * 2003-04-11 2004-10-28 Pr Pharmaceuticals Inc. Procede de preparation de conjugues de proteines specifiques de site
WO2007128901A1 (fr) * 2006-04-27 2007-11-15 Compagnie Laitiere Europeenne Utilisation de l'alpha-lactalbumine pour la regulation de la glycemie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200258, Derwent World Patents Index; AN 2002-539363, XP002606666 *
TOMOHIRI T. ET AL.: "CROSS-LINKING CHEMISTRY AND BIOLOGY: DEVELOPMENT OF MULTIFUNCTIONAL PHOTOAFFINITY PROBES", THE CHEMICAL RECORD, vol. 5, 8 November 2005 (2005-11-08), pages 385 - 395, XP002606311 *

Also Published As

Publication number Publication date
WO2010115830A2 (fr) 2010-10-14
GB0905555D0 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
WO2011012816A3 (fr) Formulation pharmaceutique
WO2007119028A3 (fr) Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
WO2008078730A1 (fr) Préparation pour administration transnasale
WO2010031720A3 (fr) Nouvelle formulation d’anticorps
WO2009085990A3 (fr) Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci
WO2008136392A1 (fr) Préparation pour une administration orale
WO2011159067A3 (fr) Dérivés de thiazole en tant qu'inhibiteurs de sglt2 et composition pharmaceutique comprenant ceux-ci
WO2009051119A1 (fr) Composé de pyrimidylindoline
WO2011076212A3 (fr) Procédés de fabrication d'un principe pharmaceutiquement actif
WO2009135593A3 (fr) Formulation pharmaceutique solide à libération retardée
WO2011120903A3 (fr) Composition pharmaceutique à dissolution rapide
WO2009047321A3 (fr) Composition pharmaceutique pour l'administration sublinguale de progestérone, et son procédé de préparation
EP2316420A8 (fr) Procédé pour réduire la douleur
WO2007090661A3 (fr) Combinaison de substances actives
WO2011011351A3 (fr) Formulation pharmaceutique stable d'oméprazole pour une administration orale
WO2009060952A1 (fr) Nouvelle préparation
WO2011077239A3 (fr) Compositions pharmaceutiques d'ilopéridone à libération lente
WO2006096518A3 (fr) Preparations ameliorees de gacyclidine
EP2455085A3 (fr) Utilisation d'au moins un composé de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum
EP2335698B8 (fr) Préparation pharmaceutique solide contenant des ingrédients actifs séparés par une frontière interne
WO2010061220A3 (fr) Nouveaux procédés et polymorphes purs
WO2010115830A3 (fr) Agent pharmaceutique
WO2009014127A1 (fr) Composition pour la prévention ou le traitement d'une maladie associée à la production d'un auto-anticorps
WO2009016608A3 (fr) Compositions pharmaceutiques de fénofibrate
WO2009011420A1 (fr) Agent thérapeutique pour le diabète de type 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10711912

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10711912

Country of ref document: EP

Kind code of ref document: A2